Dr Jodie Hay

  • Research Associate (Paul O'Gorman Leukaemia Research Centre)

telephone: 01413017887
email: Jodie.Hay@glasgow.ac.uk

Paul O'Gorman Leukaemia Res Centre, Gartnavel General Hospital, 21 Shelly Road, G12 0ZD, Glasgow, G12 0XB

ORCID iDhttps://orcid.org/0000-0002-2000-2578

Publications

List by: Type | Date

Jump to: 2021 | 2019 | 2018 | 2017 | 2016
Number of items: 15.

2021

Wei, J. et al. (2021) Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nature Microbiology, 6(9), pp. 1140-1149. (doi: 10.1038/s41564-021-00947-3) (PMID:34290390) (PMCID:PMC8294260)

Walker, A. S. et al. (2021) Ct threshold values, a proxy for viral load in community SARS-CoV-2 cases, demonstrate wide variation across populations and over time. eLife, 10, e64683. (doi: 10.7554/elife.64683) (PMID:34250907) (PMCID:PMC8282332)

Conway, D.I. et al. (2021) SARS-CoV-2 positivity in asymptomatic-screened dental patients. Journal of Dental Research, 100(6), pp. 583-590. (doi: 10.1177/00220345211004849) (PMID:33779355) (PMCID:PMC8138329)

Emary, K. R. W. et al. (2021) Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet, 397(10282), pp. 1351-1362. (doi: 10.1016/S0140-6736(21)00628-0) (PMID:33798499) (PMCID:PMC8009612)

Pouwels, K. B. et al. (2021) Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey. Lancet Public Health, 6(1), e30-e38. (doi: 10.1016/s2468-2667(20)30282-6) (PMID:33308423) (PMCID:PMC7786000)

2019

Loyola, L. et al. (2019) Disrupting MLV integrase:BET protein interaction biases integration into quiescent chromatin and delays but does not eliminate tumor activation in a MYC/Runx2 mouse model. PLoS Pathogens, 15(12), e1008154. (doi: 10.1371/journal.ppat.1008154) (PMID:31815961) (PMCID:PMC6974304)

Malik, N., Dunn, K. M., Cassels, J., Hay, J. , Estell, C., Sansom, O. J. and Michie, A. M. (2019) mTORC1 activity is essential for erythropoiesis and B cell lineage commitment. Scientific Reports, 9, 16917. (doi: 10.1038/s41598-019-53141-1) (PMID:31729420) (PMCID:PMC6858379)

Hay, J. , Moles, M. W., Cassels, J. and Michie, A. M. (2019) Subcellular fractionation of primary chronic lymphocytic leukemia cells to monitor nuclear/ cytoplasmic protein trafficking. Journal of Visualized Experiments(152), e60426. (doi: 10.3791/60426) (PMID:31710039)

Hay, J. , Gilroy, K., Huser, C. , Kilbey, A., Mcdonald, A., MacCallum, A., Holroyd, A. , Cameron, E. and Neil, J. C. (2019) Collaboration of MYC and RUNX2 in lymphoma simulates T‐cell receptor signaling and attenuates p53 pathway activity. Journal of Cellular Biochemistry, 120(10), pp. 18332-18345. (doi: 10.1002/jcb.29143) (PMID:31257681) (PMCID:PMC6772115)

Cosimo, E. et al. (2019) AKT/mTORC2 inhibition activates FOXO1 function in CLL cells reducing B cell receptor-mediated survival. Clinical Cancer Research, 25(5), pp. 1574-1587. (doi: 10.1158/1078-0432.CCR-18-2036) (PMID:30559170) (PMCID:PMC6398589)

2018

Anderson, G. et al. (2018) RUNX-mediated growth arrest and senescence are attenuated by diverse mechanisms in cells expressing RUNX1 fusion oncoproteins. Journal of Cellular Biochemistry, 119(3), pp. 2750-2762. (doi: 10.1002/jcb.26443) (PMID:29052866) (PMCID:PMC5813226)

2017

Hay, J. F. , Lappin, K., Liberante, F., Kettyle, L. M., Matchett, K. B., Thompson, A. and Mills, K. I. (2017) Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy. Oncotarget, 8(40), pp. 67891-67903. (doi: 10.18632/oncotarget.18910) (PMID:28723639) (PMCID:PMC5620222)

Neil, J. C. , Hay, J. and Borland, G. (2017) RUNX oncoproteins and miRNA networks. Oncotarget, 8(38), pp. 62818-62819. (doi: 10.18632/oncotarget.20673) (PMID:28968950) (PMCID:PMC5609882)

Neil, J. C. , Gilroy, K., Borland, G., Hay, J. , Terry, A. and Kilbey, A. (2017) The RUNX genes as conditional oncogenes: insights from retroviral targeting and mouse models. In: Groner, Y., Ito, Y., Liu, P., Neil, J. C., Speck, N. A. and van Wijnen, A. (eds.) RUNX Proteins in Development and Cancer. Series: Advances in experimental medicine and biology (962). Springer, pp. 247-264. ISBN 9789811032318 (doi:10.1007/978-981-10-3233-2_16)

2016

Borland, G. et al. (2016) Addiction to Runx1 is partially attenuated by loss of p53 in the Eμ-Myc lymphoma model. Oncotarget, 7(17), pp. 22973-22987. (doi: 10.18632/oncotarget.8554) (PMID:27056890) (PMCID:PMC5029604)

This list was generated on Wed Sep 22 18:21:34 2021 BST.
Number of items: 15.

Articles

Wei, J. et al. (2021) Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nature Microbiology, 6(9), pp. 1140-1149. (doi: 10.1038/s41564-021-00947-3) (PMID:34290390) (PMCID:PMC8294260)

Walker, A. S. et al. (2021) Ct threshold values, a proxy for viral load in community SARS-CoV-2 cases, demonstrate wide variation across populations and over time. eLife, 10, e64683. (doi: 10.7554/elife.64683) (PMID:34250907) (PMCID:PMC8282332)

Conway, D.I. et al. (2021) SARS-CoV-2 positivity in asymptomatic-screened dental patients. Journal of Dental Research, 100(6), pp. 583-590. (doi: 10.1177/00220345211004849) (PMID:33779355) (PMCID:PMC8138329)

Emary, K. R. W. et al. (2021) Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet, 397(10282), pp. 1351-1362. (doi: 10.1016/S0140-6736(21)00628-0) (PMID:33798499) (PMCID:PMC8009612)

Pouwels, K. B. et al. (2021) Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey. Lancet Public Health, 6(1), e30-e38. (doi: 10.1016/s2468-2667(20)30282-6) (PMID:33308423) (PMCID:PMC7786000)

Loyola, L. et al. (2019) Disrupting MLV integrase:BET protein interaction biases integration into quiescent chromatin and delays but does not eliminate tumor activation in a MYC/Runx2 mouse model. PLoS Pathogens, 15(12), e1008154. (doi: 10.1371/journal.ppat.1008154) (PMID:31815961) (PMCID:PMC6974304)

Malik, N., Dunn, K. M., Cassels, J., Hay, J. , Estell, C., Sansom, O. J. and Michie, A. M. (2019) mTORC1 activity is essential for erythropoiesis and B cell lineage commitment. Scientific Reports, 9, 16917. (doi: 10.1038/s41598-019-53141-1) (PMID:31729420) (PMCID:PMC6858379)

Hay, J. , Moles, M. W., Cassels, J. and Michie, A. M. (2019) Subcellular fractionation of primary chronic lymphocytic leukemia cells to monitor nuclear/ cytoplasmic protein trafficking. Journal of Visualized Experiments(152), e60426. (doi: 10.3791/60426) (PMID:31710039)

Hay, J. , Gilroy, K., Huser, C. , Kilbey, A., Mcdonald, A., MacCallum, A., Holroyd, A. , Cameron, E. and Neil, J. C. (2019) Collaboration of MYC and RUNX2 in lymphoma simulates T‐cell receptor signaling and attenuates p53 pathway activity. Journal of Cellular Biochemistry, 120(10), pp. 18332-18345. (doi: 10.1002/jcb.29143) (PMID:31257681) (PMCID:PMC6772115)

Cosimo, E. et al. (2019) AKT/mTORC2 inhibition activates FOXO1 function in CLL cells reducing B cell receptor-mediated survival. Clinical Cancer Research, 25(5), pp. 1574-1587. (doi: 10.1158/1078-0432.CCR-18-2036) (PMID:30559170) (PMCID:PMC6398589)

Anderson, G. et al. (2018) RUNX-mediated growth arrest and senescence are attenuated by diverse mechanisms in cells expressing RUNX1 fusion oncoproteins. Journal of Cellular Biochemistry, 119(3), pp. 2750-2762. (doi: 10.1002/jcb.26443) (PMID:29052866) (PMCID:PMC5813226)

Hay, J. F. , Lappin, K., Liberante, F., Kettyle, L. M., Matchett, K. B., Thompson, A. and Mills, K. I. (2017) Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy. Oncotarget, 8(40), pp. 67891-67903. (doi: 10.18632/oncotarget.18910) (PMID:28723639) (PMCID:PMC5620222)

Neil, J. C. , Hay, J. and Borland, G. (2017) RUNX oncoproteins and miRNA networks. Oncotarget, 8(38), pp. 62818-62819. (doi: 10.18632/oncotarget.20673) (PMID:28968950) (PMCID:PMC5609882)

Borland, G. et al. (2016) Addiction to Runx1 is partially attenuated by loss of p53 in the Eμ-Myc lymphoma model. Oncotarget, 7(17), pp. 22973-22987. (doi: 10.18632/oncotarget.8554) (PMID:27056890) (PMCID:PMC5029604)

Book Sections

Neil, J. C. , Gilroy, K., Borland, G., Hay, J. , Terry, A. and Kilbey, A. (2017) The RUNX genes as conditional oncogenes: insights from retroviral targeting and mouse models. In: Groner, Y., Ito, Y., Liu, P., Neil, J. C., Speck, N. A. and van Wijnen, A. (eds.) RUNX Proteins in Development and Cancer. Series: Advances in experimental medicine and biology (962). Springer, pp. 247-264. ISBN 9789811032318 (doi:10.1007/978-981-10-3233-2_16)

This list was generated on Wed Sep 22 18:21:34 2021 BST.